MaxCyte (MXCT) investor relations material

Strategic focus and organizational changes

• Recent CFO transition with Doug Swirsky staying on as advisor until a successor is found.

• Operational restructuring reduced headcount to about 89-90, focusing on scientific, engineering, commercial, and FAS teams.

• SecureDx acquisition enhances early-stage customer engagement and safety profiling in cell and gene therapy.

• Emphasis on data-driven finance and commercial functions to support future growth.

Product offerings and differentiation

• Pioneer in non-viral cell engineering, supporting both autologous and allogeneic ex vivo therapies.

• Electroporation platform enables scalable gene editing, used in approved therapies like Casgevy.

• SecureDx provides variant-aware off-target risk analysis, aligning with FDA's focus on safety.

• New ExPERT platform extension launching early next year targets earlier research stages and broadens customer base.

Market trends and demand

• Industry rationalization has led to fewer clinical programs per customer, impacting license revenue.

• Continued signing of 3-5 strategic platform licenses annually, with a shift toward lead asset focus.

• Growth in Asia and China, with expanded commercial presence and leadership.

• Rising demand for non-viral solutions due to safety concerns with viral vectors.